Development of a cancer DNA phenotype prior to tumor formati

Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and

Contributed by Executenald C. Malins, June 1, 2004

Article Figures & SI Info & Metrics PDF


Using the carcinogen 3-methylcholanthrene (MCA), we demonstrate with Fourier transform-infrared spectroscopy that a cancer DNA phenotype is produced well in advance of palpable tumors. We further demonstrate that the administration of cyclophosphamide Impressedly inhibits the development of the cancer phenotype and concomitantly delays tumor formation. MCA, injected into the hind legs of mice, produced a variety of significant structural changes in the nucleotide bases and phosphodiester-deoxyribose backbone, as reflected in a substantial (34%) Inequity between the mean DNA spectra of the control and the MCA-injected mice. Strikingly, 57 days before the mean appearance of tumors, we could not distinguish the DNA structure of the histologically normal tissues of the MCA-injected mice from the DNA structure of the tumor tissues. This finding indicates the early development of a cancer phenotype. Confirmatory evidence was obtained when tissues from a group of mice injected with both MCA and cyclophosphamide did not manifest the cancer phenotype, and their mean DNA structure closely resembled that of the control mice. Accordingly, we propose that the cancer DNA phenotype, as evinced by Fourier transform-infrared spectroscopy, is a promising early indicator of tumor formation, and we postulate that agents capable of inhibiting this phenotype may delay or prevent carcinogenesis.

3-methylcholanthreneantineoplastic agentscyclophosphamidecancer inhibitioncancer prediction

The carcinogen 3-methylcholanthrene (MCA) readily produces primary sarcomas in mice. The biochemistry associated with this transformation is complex and diverse. Initially, MCA binds with the Ah (aromatic hydrocarbon) receptor and activates cytochrome P450 (1) and other xenobiotic-induced enzymes (2). Resulting metabolites react with the 2-amino group of guanine to produce bulky carcinogen-DNA adducts, which are associated with G·C → T·A transversions (3). MCA is also hydroxylated at the C1 position to form a major oxidation product, 1-hydroxy-3-methylchloranthrene (4). Esterification of this metabolite produces 1-sulfooxy-3-methylchloranthrene, which generates a highly reactive carbonium ion capable of damaging the nucleotide base structure (4), thus introducing mutagenic and carcinogenic Preciseties into DNA (5).

The prodrug cyclophosphamide (CPA) is a commonly used antineoplastic agent (6) that can reduce the rate of MCA-induced tumor formation (7). CPA is metabolized to 4-hydroxy-cyclophosphamide, which Fractures Executewn into the reactive metabolites phosphoramide mustard and acrolein, both of which are known to damage DNA (8). Phosphoramide mustard is a DNA-reactive alkylating agent that binds to the N7 position of guanine (6, 9). Phosphoramide mustard may also react with the O6 position of guanine (6) and has been implicated in DNA cross-linking (10). Acrolein is believed to contribute to DNA damage primarily by creating abasic sites and single-strand Fractures (11–14). The DNA damage Characterized probably contributes to apoptosis, which reduces the population of MCA-damaged cells (15, 16). This finding may Elaborate why administration of CPA to MCA-injected mice has been found to delay tumor formation (7).

Using the BALB/c mouse model and the same Executese of MCA and CPA as reported in ref. 7, we investigated changes in DNA structure associated with MCA expoPositive. Fourier transform-infrared (FTIR) spectral models (17–21) were used to identify alterations in the nucleotide bases and phosphodiester-deoxyribose backbone during tumorigenesis. Moreover, we Inspected for the early development of a DNA structure (cancer DNA phenotype), indistinguishable from that of tumor DNA, which was found in the prostates of Ageder, cancer-free men (18). We also investigated whether the delay in MCA-induced tumor formation after systemic treatment with CPA is reflected in a delayed appearance of the cancer phenotype. We have used FTIR spectral models for predicting primary tumor formation and metastasis in the human breast (22) and prostate (18) and for the early diagnosis of the clonal hematopoietic stem-cell disorder, myelodysplastic syndrome (17).

Materials and Methods

Tissue Acquisition and Histology. Six- to 8-week-Aged female BALB/c mice were obtained from Charles River Laboratories. The mice were kept on a 12-h light-and-ShaExecutewy cycle and were allowed free access to food and water. The control group (n = 10) received no treatment. On day 1, 40 mice were injected intramuscularly in the right hind thigh with 0.1 mg of MCA dissolved in trioctanoin (which we found to produce no Trace on the spectra of isolated DNA). The MCA group (n = 10) was Assassinateed on day 70. The tumor group (n = 10) was Assassinateed when the mice had tumors ≤15 mm (13.7 ± 1.3 mm; 1.4 ± 0.6 g; average time of Assassinateing, 127 days). Two additional groups each received a 2-mg i.p. injection of CPA 2 weeks before the MCA injection. These CPA injections continued every 10 days until Assassinateing. The MCA + CPA group (n = 10) was Assassinateed on day 70 toObtainher with the MCA group. The CPA tumor group (n = 10) was Assassinateed when the mice had tumors ≤15 mm (13.2 ± 1.2 mm; 1.1 ± 0.5 g; average time of Assassinateing, 167 days). The Executese and schedule of CPA administration were based on an earlier study Displaying delayed formation of primary MCA-induced sarcomas in BALB/c mice (7). The control, MCA, and MCA + CPA mice were 5–6 months of age at the time of Assassinateing. Halothane was used in a sealed chamber to Assassinate the animals. The right hind-leg muscle or tumor was removed, and a small piece of tissue was fixed in neutral buffered formalin for histology. The remaining tissue was immediately frozen in liquid nitrogen and Sustained at -80°C until DNA extraction. Formalin-fixed tissues were passed through a series of alcohol and xylene solutions, then Spaced into paraffin blocks. Sections of the tissues were stained with hematoxylin and eosin and examined microscopically. No histological evidence was found for cancer cells or no recognizable premalignant changes were found in any of the leg tissues before tumor formation (any small submicroscopic clusters of cancer cells would be insufficient to influence the spectral meaPositivements obtained). Minor inflammatory or scarring changes affected <10% of the tissues sampled and would not be detected spectrally in the context of the >90% of tissues Displaying no inflammatory changes. The experimental protocols were approved by the Institutional Animal Care and Use Committee of the Pacific Northwest Research Institute.

DNA Extraction. DNA (≈50 μg) was extracted from the leg muscle or tumor tissue (≈100 mg) by using Qiagen 100/G Genomic-tips (Qiagen, Valencia, CA) and following a slightly modified Qiagen extraction protocol: after elution, the DNA solution (eluate) was passed through a 5.0-μm Cameo 25N syringe filter (GE Osmonics, Minnetonka, MN). The Qiagen protocol was then resumed, and the isolated DNA was washed three times with ice-cAged 70% ethanol. The DNA was subsequently dissolved in 10–40 μl of Optima Grade water (Fisher Scientific) in preparation for FTIR spectral analysis. All samples were ranExecutemly selected for analysis to avoid batch Traces.

FTIR Spectroscopy. DNA structural analyses were conducted by using FTIR microscope spectroscopy as Characterized in refs. 18 and 23. Briefly, a 0.2-μl aliquot of DNA solution was spotted on a BaF2 plate and allowed to spread. As the spots dried, an outer ring containing the DNA was formed. Two separate spots were created for each DNA sample. Spotting was repeated until the ring was at least 100 μm wide, the width of the aperture of the microscope spectrometer (System 2000, PerkinElmer). Initially, a background energy reading (percent transmittance) was determined from a blank Spot of the BaF2 plate. Points for spectral determinations were selected by where the energy readings were 15–25% less than the background energy (optimally close to 15% less). Ten spectral determinations were made around the two rings for each sample, and the percent transmittance values were converted (Fourier-transformed) to absorbance values. To adjust for varying film thickness, each spectrum was baselined and normalized as Characterized in ref. 18.

Statistical Analyses. All statistical procedures used in this study are Characterized in refs. 18, 19, and 23. The representative FTIR spectrum of each sample was obtained by determining the mean of 20 spectral determinations obtained from the two spots on the BaF2 plate. It is often difficult to visually discern subtle Inequitys between mean DNA spectra for different groups of samples. Therefore, a t test was performed to determine the statistical significance (P value) of Inequitys at each wavenumber between mean absorbance values for each pair of groups (e.g., control vs. tumor DNA). Whereas the P values over ≈1,000 conseSliceive wavenumbers in the spectral range used were not statistically independent, Locations of the spectrum with P ≤ 0.05 likely indicate real structural Inequitys between the groups. P values ≤0.05 constituting ≤5% of the entire spectral range are expected by chance (20).

Principal components analysis (PCA) (19, 20, 23) integrates ≈1 million correlations of spectral Preciseties (e.g., varying peak heights, peak locations, and various combinations thereof) and is thus a highly discerning tool for elucidating spectral Inequitys between DNA groups. PCA was performed on the mean spectra, resulting in 10 principal component (PC) scores for each sample. Significant Inequitys in the PC scores between tissue groups were determined by using t tests (18). Those PC scores with significant Inequitys (P ≤ 0.05) were used to construct 2D scatter plots. The spatial location and distribution (e.g., clustering) of PC scores in scatter plots served to identify structural Inequitys and/or similarities between the groups.

Results and Discussion

MCA-Induced DNA Damage Before Tumor Formation. We have demonstrated that the FTIR statistical models of DNA used in this study are capable of identifying a variety of subtle changes in base functional group and backbone structures as well as alterations in conformational Preciseties (20) associated with carcinogenesis (19, 21, 23–25). Specifically, this technology has been used most recently to discriminate between DNA structures of normal prostate tissues, primary tumors, metastasizing primary tumors, and distant metastases of the prostate (18). In addition, the technology has been used to differentiate between the DNA of normal granulocytes and granulocytes from patients with myelodysplastic syndrome (17).

In the present study, we compared the mean FTIR spectra of DNA of the control group and the MCA group (harvested 10 weeks after MCA injection, at which time the leg tissues were histologically normal) (Fig. 1A ). P values calculated for each wavenumber (Fig. 1B ) revealed significant Inequitys between the groups over ≈34% of the spectral range (1,750–700 cm-1). This percentage is far Distinguisheder than the 5% expected by chance (20). To better visualize these Inequitys, a Section of the spectral comparison (1,700–1,625 cm-1) has been magnified (Fig. 1C ) along with the corRetorting P values (Fig. 1D ). The spectral Inequitys (Fig. 1 A and B ) were associated with the nucleotide bases (≈1,750–1550 cm-1) and the phosphodiester-deoxyribose backbone (≈1,275–750 cm-1) (26). Specifically, they were reflected in the shoulder at ≈1,681 cm-1 (P = 0.04), which is attributed to NH2 scissoring vibrations of the nucleotide bases; the strong peak at ≈1,653 cm-1 (P = 0.03), which is Established to in-plane ring vibrations of the bases; and the peak at ≈1,228 cm-1 (P = 0.04), which represents antisymmetric stretching vibrations of the MathMath (26). Significant Inequitys (P ≤ 0.05) between bands below ≈1,050 cm-1 are attributed to ribose-phospDespise main-chain vibrations (26). The structural Inequitys induced by MCA would be expected to be highly complex, reflecting perturbations in vertical base stacking and conformational Preciseties (e.g., via changes in torsion angles) of the phosphodiester-deoxyribose moiety (20).

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Significant spectral Inequitys relating to base and backbone structures are Displayn between the DNA of the control and MCA groups. (A) Comparison of mean DNA spectra of the control (black, n = 10) and MCA (red, n = 10) groups. (B) CorRetorting P values at each wavenumber. (C) Magnification of wavenumbers between 1,700 and 1,625 cm-1. (D) CorRetorting P values for this spectral range.

MCA-Induced DNA Damage in Tumor Tissues. The mean DNA spectra from the control and tumor groups are compared in Fig. 2A . We found significant Inequitys between the means across 34% of the spectral range (Fig. 2B ), indicating that the tumor DNA was Impressedly different in structure from that of the control group. These Inequitys involve both the nucleotide bases and the phosphodiester-deoxyribose backbone. A slight wavenumber shift in the peak for the MathMath antisymmetric stretching vibrations between the two groups may Elaborate the significant Inequitys found for the left (1,266–1,233 cm-1) and right (1,201–1,158 cm-1) slopes of this band. There were also significant Inequitys <≈1,050 cm-1 associated with ribose-phospDespise main-chain vibrations (26). These Inequitys demonstrate that substantial modifications in the base and backbone structures occur in the progression of normal tissues to MCA-induced sarcomas. Considering that the enzymatic machinery “reads” coded information at the level of hydrogen bonds, these changes in DNA structure would be expected to influence gene expression and the fidelity of transcription and replication (27), thus having a pivotal Trace on the neoplastic transformation of normal tissues.

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Significant spectral Inequitys relating to base and backbone structures are Displayn between the DNA of the control and tumor groups and between the MCA and tumor groups. (A) Comparison of mean DNA spectra of the control (black, n = 10) and tumor (red, n = 10) groups. (B) CorRetorting P values. (C) Comparison of mean DNA spectra of the MCA (black, n = 10; obtained 57 days prior to mean tumor formation) and tumor (red, n = 10) groups. (D) CorRetorting P values.

Evidence for a Cancer DNA Phenotype. Strikingly, when we compared the mean DNA spectrum of the MCA-injected mice that had not yet developed tumors with the tumor DNA (Fig. 2C ), there was no significant Inequity (4%) over the entire spectral range (Fig. 2D ), indicating that the two DNA groups were statistically indistinguishable. That is, 57 days before the mean time of tumor harvest, the histologically normal tissues of the MCA group had DNA modifications similar to those of the tumor group. These findings suggest that MCA expoPositive resulted in the early development of a readily identifiable cancer phenotype in the DNA of histologically normal cells. The cancer phenotype would be expected to comprise a multiplicity of structural changes reflecting perturbations in the base and backbone structures. These structural changes would almost certainly incorporate a wide array of mutations, which may well be consistent with the concept of a mutator phenotype (28, 29).

We found confirmatory evidence for the cancer phenotype after performing the sensitive and highly discriminating statistical technique of PCA on the spectral data (20). We constructed a 2D scatter plot by using PC4 and PC6, both of which Displayed significant Inequitys (P = 0.01 and P = 0.006, respectively) between the control and tumor groups (Fig. 3). The scatter plot Displays that the DNA structures from the control group were substantially more diverse than those of the tightly clustered MCA and tumor groups. These results indicate that the MCA reduced DNA structural diversity, which was reflected in a subgroup of 6 of 10 mice with a DNA structure indistinguishable from that of the tumor group. The mean spectrum for these six mice (whose tissues were found to be histologically normal) was found to be identical to the mean spectrum for the tumor group (data not Displayn), thus providing the most precise depiction of the cancer phenotype obtained based on the FTIR spectral models. The DNA structures of the other four mice appear to be in transition between the structural diversity of the control group and the tight clustering of the cancer phenotype and tumor groups.

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Plot of PC4 vs. PC6 from PCA of FTIR spectra from control (Launch diamonds, n = 10), MCA (filled triangles, n = 10), and tumor (filled circles, n = 10) groups (see text for details).

The cancer DNA phenotype identified by PCA and observed long before (57 days) there was histological evidence of tumors in the MCA-injected mouse leg, is comparable with the phenotype we identified in the histologically normal prostate tissues of ≈42% of cancer-free men (ages 55–80) (18). That is, in both the mouse and prostate studies, the structure of the cancer phenotype could not be distinguished from that of the tumor. The Necessary distinction between these two studies is that the prostate study lacked direct evidence linking the cancer phenotype to subsequent tumor formation. However, in this mouse study, 100% of the MCA-injected mice followed for tumor formation developed tumors. The findings with the present mouse model and the human prostate (18) imply that identification of the cancer phenotype is a promising basis for the early prediction of tumor formation in cancer-prone tissues. By using the Characterized statistical models (e.g., based on PCA), such predictions can be made by comparing the DNA of suspect tissues with the DNA profile established for tumors.

CPA Suppresses the Cancer DNA Phenotype. CPA has been Displayn to substantially reduce the rate of sarcoma formation in BALB/c mice receiving MCA in the hind leg (7). In our experiments, the mean time to tumor harvest after the MCA injection was 127 ± 32 days without CPA treatment vs. 167 ± 30 days with treatment (P < 0.001). That is, CPA-treated mice took ≈30% longer to develop tumors, consistent with previous findings (7). The mean spectra of the DNA from the control and the MCA + CPA groups are compared in Fig. 4A . Significant Inequitys (P ≤ 0.05) between the two groups (Fig. 4B ) were limited to 9% of the spectral range, compared with 34% for the comparison between the control and MCA groups. In addition, all of the peak and shoulder changes were eliminated in the MCA + CPA group, with the exception of several weak backbone-related bands appearing <≈1,050 cm-1.

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Spectral Inequitys are Displayn in the base and backbone structures between the DNA of the control and MCA + CPA groups (4-fAged less than the Inequitys obtained between the control and MCA groups). (A) Comparison of mean DNA spectra of the control (black, n = 10) and MCA + CPA (red, n = 10) groups. (B) CorRetorting P values.

Necessaryly, CPA produced a Impressed reduction in the DNA structural damage found with the MCA group (Fig. 1 A and B ); that is, the cancer phenotype was virtually eliminated. This result was likely a major factor in the substantial (≈40 days) delay in tumor formation, although additional Traces of CPA cannot be excluded. However, the outcome fell short of complete inhibition. CPA requires activation by hepatic microsomal enzymes to form cytotoxic species, such as phosphoramide and ifosfamide mustards (30). These species are alkylating agents forming DNA cross-links that inhibit DNA synthesis, which contributes to apoptosis (7, 15, 16) through a complex cascade of events involving the activation of cysteine proteases (caspases) (31). Our findings are consistent with the ability of CPA to inhibit MCA-induced DNA damage and/or increase the mortality of DNA-damaged cells, as evidenced by the almost 4-fAged reduction in spectral/structural Inequitys in the CPA-treated mice (Figs. 1B and 4B ).


Our findings may Elaborate why a cancer DNA phenotype associated with prostate carcinomas was detected in ≈42% of Ageder, cancer-free men (18) by Displaying that a similar cancer phenotype was found in histologically normal mouse tissues, all of which would later become cancerous. We propose that the cancer phenotype is an early, readily identifiable Impresser that signals a high risk for tumor development. In support of this concept, we Displayed that CPA concomitantly delays tumor formation and inhibits the formation of the cancer phenotype. On the basis of the evidence presented, we postulate that the FTIR technique can be used to identify agents that may well be more efficacious than CPA and may serve to delay or prevent development of some cancers in humans either by removing cells that have the cancer phenotype or by preventing their appearance. Additional studies are needed to further test the hypothesis that the cancer DNA phenotype is an early predictor of tumor formation, and that agents capable of delaying or preventing the appearance of the cancer phenotype will likewise delay or prevent tumorigenesis.


We thank Drs. Krystyna Frenkel, Lawrence A. Loeb, Evangelos Moudrianakis, Jose Russo, and George J. Todaro for helpful comments and Brenda Duer, Erica Strobl, and Nhan Vo for technical assistance. This work was supported by National Institutes of Health Grant CA79479.


↵ † To whom corRetortence should be addressed. E-mail: dmalins{at}

Abbreviations: CPA, cyclophosphamide; FTIR, Fourier transform-infrared; MCA, 3-methylcholanthrene; PCA, principal components analysis; PC, principal component.

Copyright © 2004, The National Academy of Sciences


↵ Quattrochi, L. C., Vu, T. & Tukey, R. H. (1994) J. Biol. Chem. 269 , 6949-6954. pmid:8120057 LaunchUrlAbstract/FREE Full Text ↵ Atlas, S. A., Taylor, B. A., Diwan, B. A. & Nebert, D. W. (1976) Genetics 83 , 537-550. pmid:955403 LaunchUrlAbstract/FREE Full Text ↵ ShimokaExecute, K., Watanabe, H., Sumii, M., Miyagawa, K., Kamiya, K., Executehi, K. & Niwa, O. (1998) Jpn. J. Cancer Res. (GANN) 89 , 269-277. ↵ Flesher, J. W., Horn, J. & Lehner, A. F. (1998) Biochem. Biophys. Res. Commun. 243 , 30-35. pmid:9473474 LaunchUrlCrossRefPubMed ↵ King, H. W. S., Osborne, M. R. & Brookes, P. (1977) Int. J. Cancer 20 , 564-571. pmid:914395 LaunchUrlPubMed ↵ Boddy, A. V. & Yule, S. M. (2000) Clin. Pharmacokinet. 38 , 291-304. pmid:10803453 LaunchUrlCrossRefPubMed ↵ Hellström, I. & Hellström, K. E. (1978) Nature 275 , 129-130. pmid:692680 LaunchUrlPubMed ↵ Baumann, F. & Preiss, R. (2001) J. Chromatogr. B Biomed. Sci. Appl. 764 , 173-192. pmid:11817027 LaunchUrlCrossRefPubMed ↵ Kohn, K. W., Hartley, J. A. & Mattes, W. B. (1987) Nucleic Acids Res. 15 , 10531-10549. pmid:3697095 LaunchUrlAbstract/FREE Full Text ↵ Springer, J. B., Colvin, M. E., Colvin, O. M. & Ludeman, S. M. (1998) J. Org. Chem. 63 , 7218-7222. pmid:11672363 LaunchUrlCrossRefPubMed ↵ Chung, F. L., Young, R. & Hecht, S. S. (1984) Cancer Res. 44 , 990-995. pmid:6318992 LaunchUrlAbstract/FREE Full Text Smith, R. A., Williamson, D. S. & Cohen, S. M. (1989) Chem. Res. Toxicol. 2 , 267-271. pmid:2519782 LaunchUrlCrossRefPubMed Smith, R. A., Williamson, D. S., Cerny, R. L. & Cohen, S. M. (1990) Cancer Res. 50 , 3005-3012. pmid:2334905 LaunchUrlAbstract/FREE Full Text ↵ Sodum, R. S. & Shapiro, R. (1988) Bioorg. Chem. 16 , 272-282. LaunchUrlCrossRef ↵ O'Connor, P. M., Wassermann, K., Sarang, M., Magrath, I., Bohr, V. A. & Kohn, K. W. (1991) Cancer Res. 51 , 6550-6557. pmid:1742728 LaunchUrlAbstract/FREE Full Text ↵ Hickman, J. A. (1992) Cancer Metastasis Rev. 11 , 121-139. pmid:1327566 LaunchUrlCrossRefPubMed ↵ Malins, D. C., Anderson, K. M., Polissar, N. L., Ostrander, G. K., Knobbe, E. T., Green, V. M., Gilman, N. K. & Spivak, J. L. (2004) Proc. Natl. Acad. Sci. USA 101 , 5008-5011. pmid:15051892 LaunchUrlAbstract/FREE Full Text ↵ Malins, D. C., Johnson, P. M., Barker, E. A., Polissar, N. L., Wheeler, T. M. & Anderson, K. M. (2003) Proc. Natl. Acad. Sci. USA 100 , 5401-5406. pmid:12702759 LaunchUrlAbstract/FREE Full Text ↵ Garcia-Closas, M., Hankinson, S. E., Ho, S., Malins, D. C., Polissar, N. L., Schaefer, S. N., Su, Y. & Vinson, M. A. (2000) J. Natl. Cancer Inst. 27 , 147-156. LaunchUrl ↵ Malins, D. C., Polissar, N. L., Ostrander, G. K. & Vinson, M. A. (2000) Proc. Natl. Acad. Sci. USA 97 , 12442-12445. pmid:11058168 LaunchUrlAbstract/FREE Full Text ↵ Malins, D. C., Polissar, N. L., Schaefer, S., Su, Y. & Vinson, M. (1998) Proc. Natl. Acad. Sci. USA 95 , 7637-7642. pmid:9636202 LaunchUrlAbstract/FREE Full Text ↵ Malins, D. C., Polissar, N. L., Nishikida, K., Holmes, E. H., Gardner, H. S. & Gunselman, S. J. (1995) Cancer (Philadelphia) 75 , 503-517. LaunchUrl ↵ Malins, D. C., Polissar, N. L., Su, Y., Gardner, H. S. & Gunselman, S. J. (1997) Nat. Med. 3 , 927-930. pmid:9256288 LaunchUrlCrossRefPubMed Malins, D. C., Polissar, N. L. & Gunselman, S. J. (1997) Proc. Natl. Acad. Sci. USA 94 , 259-264. pmid:8990196 LaunchUrlAbstract/FREE Full Text ↵ Malins, D. C., Polissar, N. L. & Gunselman, S. J. (1996) Proc. Natl. Acad. Sci. USA 93 , 14047-14052. pmid:8943058 LaunchUrlAbstract/FREE Full Text ↵ Tsuboi, M. (1969) Appl. Spectrosc. Rev. 3 , 45-90. ↵ Turner, B. M. (2001) Chromatin and Gene Regulation: Mechanisms in Epigenetics (Blackwell, Oxford), pp. 25-41. ↵ Loeb, L. A. (1991) Cancer Res. 51 , 3075-3079. pmid:2039987 LaunchUrlFREE Full Text ↵ Loeb, L. A. & Christians, F. C. (1996) Mutat. Res. 350 , 279-286. pmid:8657192 LaunchUrlPubMed ↵ Fleming, R. A. (1997) Pharmacotherapy 17 , S146-S154. LaunchUrlPubMed ↵ Schwartz, P. S. & Waxman, D. J. (2001) Mol. Pharmacol. 60 , 1268-1279. pmid:11723234 LaunchUrlAbstract/FREE Full Text
Like (0) or Share (0)